Chemotherapy in the management of malignant tumors of salivary gland origin

Scott A. Laurie, Athanassios Argiris

Research output: Chapter in Book/Report/Conference proceedingChapter


There are insufficient data to support the routine use of adjuvant or neoadjuvant chemotherapy. Chemotherapy should be reserved for the palliation of disease-related symptoms and for patients at risk of developing such symptoms due to rapid progression of locally recurrent or metastatic disease. In patients with indolent disease and without symptoms, watchful waiting is acceptable, and may be the preferred approach. The different histological subtypes of malignant tumors of salivary gland origin may have differing responsiveness to chemotherapeutic agents. The published literature on the role of systemic therapy in malignancies of the salivary glands is inadequate and limits the generation of evidence-based recommendations. All patients should be considered for participation in clinical trials to help define the role of systemic therapies in these tumors. As the understanding of the underlying molecular abnormalities of these tumors grows, there will be opportunities for the development and testing of novel, targeted agents.

Original languageEnglish (US)
Title of host publicationSalivary Gland Disorders
PublisherSpringer Berlin Heidelberg
Number of pages18
ISBN (Print)9783540470700
StatePublished - 2007
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Chemotherapy in the management of malignant tumors of salivary gland origin'. Together they form a unique fingerprint.

Cite this